Paper Details

  1. Home
  2. Paper Details

Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Author: BenzaRaymond L, BusseDennis, GhioStefano, GhofraniHossein-Ardeschir, GrünigEkkehard, HoeperMarius M, JansaPavel, JingZhi-Cheng, KimNick H, LanglebenDavid, MeierChristian, SimonneauGérald, WangChen

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review examines the efficacy and safety of riociguat, a medication used to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), in clinical trials. The review found that riociguat is effective in treating PAH and CTEPH and that its effects are sustained over the long term.
Paper Details　
Original Abstract of the Article :
In the Phase III PATENT-1 (NCT00810693) and CHEST-1 (NCT00855465) studies, riociguat demonstrated efficacy vs placebo in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Clinical effects were maintained at 2 years in the long-term extensi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.healun.2021.06.020

データ提供：米国国立医学図書館（NLM）

Effect of Riociguat on Right Ventricular Function in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are serious conditions that can lead to right ventricular dysfunction. Riociguat, a novel drug, has shown promise in treating these conditions. This study examines the effects of riociguat on right ventricular function in patients with PAH and CTEPH. The authors reviewed data from the PATENT-1, CHEST-1, PATENT-2, and CHEST-2 clinical trials and found that riociguat demonstrated efficacy in improving right ventricular function and maintaining clinical effects over a two-year period.

Evaluating the Impact of Riociguat on Right Ventricular Function

This study provides evidence that riociguat is an effective treatment for PAH and CTEPH, with sustained benefits for right ventricular function over time. The findings suggest that riociguat could be a valuable option for managing these challenging conditions.

PAH and CTEPH: A Camel's Perspective

Imagine a camel struggling to climb a steep sand dune, its heart laboring to maintain its strength. PAH and CTEPH, like a relentless desert wind, can strain the heart, making it difficult to breathe and function normally. This study offers a glimpse of hope in the vast desert of pulmonary hypertension, highlighting the potential of riociguat to improve quality of life for patients with these conditions. It's a reminder that scientific advancements continue to offer new avenues for treating complex diseases and improving patient outcomes.

Dr.Camel's Conclusion

This research highlights the positive effects of riociguat on right ventricular function in patients with PAH and CTEPH. The findings suggest that riociguat could be a valuable treatment option for these challenging conditions, providing hope for patients seeking relief from the debilitating symptoms of pulmonary hypertension.

Date :
  1. Date Completed 2022-02-16
  2. Date Revised 2022-02-16
Further Info :

Pubmed ID

34353714

DOI: Digital Object Identifier

10.1016/j.healun.2021.06.020

Related Literature

Article Analysis
・Effects of riociguat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.